The global cartilage repair/regeneration market is projected to reach USD 1,810 million by 2027 from USD 774 million in 2020, at a CAGR of 15.5% during the forecast period 2021 to 2027. Cartilage is a colossally strong and fibrous flexible tissue which is present at many in major parts of the body serving many purposes. The hyaline cartilage which is present at a joint referred to the articular cartilage. In case of injury, ageing or diseases such as rheumatoid arthritis, osteoarthritis causes painful friction or injury to the cartilage. Because of not having blood vessels, cartilage does not heal itself well. So there is a need for the treatment options to aid the regeneration or repair the cartilage. Elective procedures are being denied (cancelled/postponed) in order to allocate or redirect scarce capacities and resources (such as hospital beds and patient care staff) to COVID-19 patient care. Moreover, to combat the increased number of positive COVID-19 cases, several countries have implemented lockdowns and curfews. Patients are unable to visit hospitals, outpatient clinics, or clinics due to the lockdowns. During the anticipated period, this temporary denial of wound care services, cancer care surgeries/therapies, and other healthcare services is expected to hamper the growth of the cartilage repair/regeneration market. The number of firms working on the development of cartilage regeneration products has expanded dramatically in recent years as a result of expanding government investments in regenerative medicine for cartilage regeneration research. The number of clinical trials and the development of novel technologies for cartilage regeneration has increased as a result of these considerations. Major competitors in this market are investing heavily in R&D, resulting in a robust pipeline of products based on diverse cartilage restoration techniques.